blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3069731

EP3069731 - ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING SAME [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  16.10.2020
Database last updated on 22.08.2024
FormerExamination is in progress
Status updated on  20.10.2017
FormerRequest for examination was made
Status updated on  24.03.2017
Most recent event   Tooltip16.10.2020New entry: Date of cancellation oral proceedings 
16.10.2020Withdrawal of applicationpublished on 18.11.2020  [2020/47]
Applicant(s)For all designated states
Teva Pharmaceuticals International GmbH
Schlüsselstrasse 12
8645 Jona / CH
[2017/30]
Former [2016/38]For all designated states
Labrys Biologics Inc.
735 Galveston Drive
Redwood City, CA 94063 / US
Inventor(s)01 / ZELLER, Joerg
1002 Sunnyside Boulevard
Ann Arbor, MI Michigan 48103 / US
02 / POULSEN, Kristian Todd
2080 Third Street, No. 7
San Francisco, CA California 94107 / US
03 / ABDICHE, Yasmina Noubia
183 Ada Avenue, Unit A
Mountain View, CA California 94043 / US
04 / PONS, Jaume
1723 Hickory Avenue
San Bruno, CA California 94066 / US
05 / ROSENTHAL, Arnon
150 Normandy Lane
Woodside, CA California 94062 / US
06 / COLLIER, Sierra Jones
521 - 7th Avenue
Menlo Park, CA California 94025 / US
 [2016/38]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2016/38]
Application number, filing date16154411.902.11.2006
[2016/38]
Priority number, dateUS20050736623P14.11.2005         Original published format: US 736623 P
[2016/38]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3069731
Date:21.09.2016
Language:EN
[2016/38]
Search report(s)(Supplementary) European search report - dispatched on:EP18.07.2016
ClassificationIPC:A61K39/395, A61P5/24
[2016/38]
CPC:
A61K31/4045 (EP,US); C07K16/18 (NO,US); A61K39/395 (KR,NO);
A61K39/3955 (EP,US); A61P25/00 (EP); A61P25/06 (EP);
A61P29/00 (EP); A61P43/00 (EP); A61P5/00 (EP);
A61P5/24 (EP); A61P9/00 (EP); C07K16/00 (KR);
C07K16/26 (EP,US); A61K2039/505 (EP,US); C07K2317/21 (US);
C07K2317/24 (US); C07K2317/33 (EP,US); C07K2317/34 (EP,US);
C07K2317/52 (US); C07K2317/55 (EP,US); C07K2317/56 (US);
C07K2317/565 (EP,US); C07K2317/567 (US); C07K2317/70 (EP,US);
C07K2317/71 (US); C07K2317/76 (EP,US); C07K2317/92 (EP,US);
C07K2317/94 (US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/17]
Former [2016/38]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
Extension statesAL20.03.2017
BA20.03.2017
HR20.03.2017
MK20.03.2017
RS20.03.2017
TitleGerman:ANTAGONISTISCHE ANTIKÖRPER GEGEN CALCITONINGEN-ASSOZIIERTES PEPTID UND VERFAHREN DAMIT[2016/38]
English:ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING SAME[2016/38]
French:ANTAGONISTES D'ANTICORPS DIRIGÉS CONTRE UN PEPTIDE ASSOCIÉ AU GÈNE DE LA CALCITONINE ET PROCÉDÉS LES UTILISANT[2016/38]
Examination procedure05.02.2016Date on which the examining division has become responsible
20.03.2017Examination requested  [2017/17]
03.05.2017Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
13.07.2017Amendment by applicant (claims and/or description)
20.10.2017Despatch of a communication from the examining division (Time limit: M04)
08.01.2018Observations by third parties
28.02.2018Reply to a communication from the examining division
07.03.2018Observations by third parties
22.03.2018Despatch of a communication from the examining division (Time limit: M04)
01.08.2018Reply to a communication from the examining division
27.11.2018Despatch of a communication from the examining division (Time limit: M06)
28.05.2019Reply to a communication from the examining division
14.10.2020Application withdrawn by applicant  [2020/47]
14.10.2020Cancellation of oral proceeding that was planned for 11.11.2020
11.11.2020Date of oral proceedings (cancelled)
Parent application(s)   TooltipEP06809207.1  / EP1957106
EP11166787.9  / EP2380592
Divisional application(s)EP20200867.8
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
13.07.2017Request for further processing filed
13.07.2017Full payment received (date of receipt of payment)
Request granted
25.07.2017Decision despatched
Fees paidRenewal fee
05.02.2016Renewal fee patent year 03
05.02.2016Renewal fee patent year 04
05.02.2016Renewal fee patent year 05
05.02.2016Renewal fee patent year 06
05.02.2016Renewal fee patent year 07
05.02.2016Renewal fee patent year 08
05.02.2016Renewal fee patent year 09
05.02.2016Renewal fee patent year 10
23.11.2016Renewal fee patent year 11
24.11.2017Renewal fee patent year 12
22.11.2018Renewal fee patent year 13
26.11.2019Renewal fee patent year 14
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]US2005234054  (MUELLER STEPHAN G [DE], et al) [Y] 1-18 * paragraphs [0065] , [0066] *;
 [Y]  - TAN K K ET AL, "Calcitonin gene-related peptide as an endogenous vasodilator: immunoblockade studies in vivo with an anti-calcitonin gene-related peptide monoclonal antibody and its Fab' fragment.", CLINICAL SCIENCE (LONDON, ENGLAND : 1979) DEC 1995, (199512), vol. 89, no. 6, ISSN 0143-5221, pages 565 - 573, XP009082539 [Y] 1-18 * the whole document *

DOI:   http://dx.doi.org/10.1042/cs0890565
 [Y]  - FROBERT Y ET AL, "A sensitive sandwich enzyme immunoassay for calcitonin gene-related peptide (CGRP): characterization and application.", PEPTIDES 1999, (1999), vol. 20, no. 2, ISSN 0196-9781, pages 275 - 284, XP002430636 [Y] 1-18 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0196-9781(98)00172-7
 [Y]  - HONG KI WHAN ET AL, "Pharmacological coupling and functional role for CGRP receptors in the vasodilation of rat pial arterioles", AMERICAN JOURNAL OF PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, US, (19960101), vol. 270, no. 1, ISSN 0002-9513, pages H317 - H323, XP009190587 [Y] 1-18 * page H320, column r, line 1 - page H321, column r, paragraph 3 *
 [Y]  - BUCKLEY T L ET AL, "THE PARTIAL INHINITION OF INFLAMMATORY RESPONSES INDUCED BY CAPSAICIN USING THE FAB FRAGMENT OF A SELECTIVE CALCITONIN GENE-RELATED PEPTIDE ANTISERUM IN RABBIT SKIN", NEUROSCIENCE, NEW YORK, NY, US, (1992), vol. 48, no. 4, ISSN 0306-4522, pages 963 - 968, XP000563679 [Y] 1-18 * the whole document *

DOI:   http://dx.doi.org/10.1016/0306-4522(92)90284-9
 [Y]  - BALINT R F ET AL, "ANTIBODY ENGINEERING BY PARSIMONIOUS MUTAGENESIS", GENE, ELSEVIER, AMSTERDAM, NL, (19931227), vol. 137, no. 1, ISSN 0378-1119, pages 109 - 118, XP002031537 [Y] 1-18 * page 110, column R *

DOI:   http://dx.doi.org/10.1016/0378-1119(93)90258-5
 [Y]  - ASAHINA A ET AL, "Specific induction of cAMP in Langerhans cells by calcitonin gene-related peptide: Relevance to functional effects", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1995), vol. 92, no. 18, ISSN 0027-8424, pages 8323 - 8327, XP002759007 [Y] 1-18 * abstract *
 [A]  - LITTLE M ET AL, "Of mice and men: hybridoma and recombinant antibodies", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, (20000801), vol. 21, no. 8, ISSN 0167-5699, pages 364 - 370, XP004215163 [A] 1-18 * abstract *

DOI:   http://dx.doi.org/10.1016/S0167-5699(00)01668-6
 [A]  - HOLT L J ET AL, "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, (200311), vol. 21, no. 11, ISSN 0167-7799, pages 484 - 490, XP004467495 [A] 1-18 * abstract *

DOI:   http://dx.doi.org/10.1016/j.tibtech.2003.08.007
 [A]  - DAVIES J ET AL, "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, (199609), vol. 2, no. 3, ISSN 1380-2933, pages 169 - 179, XP004070292 [A] 1-18 * abstract *

DOI:   http://dx.doi.org/10.1016/S1380-2933(96)00045-0
by applicantUS3773919
 EP0003089
 US4485045
 US4544545
 US4676980
 US4683195
 US4683202
 WO8704462
 US4754065
 GB2200651
 US4777127
 US4800159
 US4816567
 EP0345242
 WO9007936
 WO9011092
 WO9100360
 WO9102805
 US5013556
 US5047335
 WO9114445
 WO9220373
 EP0519596
 EP0524968
 WO9303769
 WO9306213
 WO9311230
 WO9311218
 US5219740
 WO9319191
 WO9325698
 WO9325234
 US5278299
 WO9404690
 WO9412649
 WO9413622
 WO9423697
 WO9428938
 WO9500655
 WO9507994
 WO9511984
 WO9513796
 US5422120
 WO9530763
 US5500362
 US5510261
 WO9617072
 US5530101
 US5545807
 US5545806
 US5565332
 US5569825
 US5580717
 US5580859
 US5585089
 US5625126
 US5633425
 US5661016
 WO9742338
 US5693761
 US5693762
 US5733743
 US5750373
 GB9809951D
 US5807715
 US5814482
 US5821337
 US5866692
 US5981568
 WO9958572
 US5997867
 US6054297
 WO0053211
 US6180370
 US6180377
 US6210671
 WO0127160
 US6265150
 US6331415
 US6350861
 US6376471
 US6413942
 US6436908
 WO2004058184
    - WYON ET AL., SCAND. J. UROL. NEPHROL., (2001), vol. 35, pages 92 - 96
    - WYON ET AL., MENOPAUSE, (2000), vol. 7, no. 1, pages 25 - 30
    - FREEDMAN AM, J. HUMAN BIOL., (2001), vol. 13, pages 453 - 464
    - KATOVICH ET AL., PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY & MEDICINE, (1990), vol. 193, no. 2, pages 129 - 35
    - BERENDSEN ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY, (2001), vol. 419, no. 1, pages 47 - 54
    - DURHAM, N., ENGL. J. MED., (2004), vol. 350, pages 1073 - 1075
    - GOADSBY ET AL., ANN. NEUROL., (1990), vol. 28, pages 183 - 7
    - LASSEN ET AL., CEPHALALGIA, (2002), vol. 22, pages 54 - 61
    - BRAIN, S. ET AL., TRENDS IN PHARMACOLOGICAL SCIENCES, (2002), vol. 23, pages 51 - 53
    - GOADSBY ET AL., BRAIN, (2002), vol. 125, pages 1392 - 401
    - ARULMANI ET AL., CEPHALALGIA, (2005), vol. 25, pages 1082 - 1090
    - GIFFIN ET AL., CEPHALALGIA, (2003), vol. 23, pages 287 - 292
    - ARULMANI ET AL., EUR. J. PHARMACOL., (2004), vol. 500, pages 315 - 330
    - GOADSBY ET AL., NEW ENGL. J. MED., (2002), vol. 346, no. 4, pages 257 - 275
    - GOADSBY, P.J. ET AL., NEW ENGL. J. MED., (2002), vol. 346, no. 4, pages 257 - 275
    - EUR. J. IMMUNOL., (1999), vol. 29, pages 2613 - 2624
    - Methods in Molecular Biology, HUMANA PRESS
    - Methods in Enzymology, ACADEMIC PRESS, INC.
    - Handbook of Experimental Immunology
    - KOHLER; MILSTEIN, NATURE, (1975), vol. 256, page 495
    - MCCAFFERTY ET AL., NATURE, (1990), vol. 348, pages 552 - 554
    - VAUGHAN ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 309 - 314
    - SHEETS ET AL., PNAS, (USA, (1998), vol. 95, pages 6157 - 6162
    - HOOGENBOOM; WINTER, J. MOL. BIOL., (1991), vol. 227, page 381
    - MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, page 581
    - COLE ET AL., Monoclonal Antibodies and Cancer Therapy, ALAN R. LISS, (1985), page 77
    - BOERNER ET AL., J. IMMUNOL., (1991), vol. 147, no. 1, pages 86 - 95
    - AL-LAZIKANI ET AL., J. MOLEC. BIOL., (1997), vol. 273, pages 927 - 948
    - RAVETCH; KINET, ANN. REV. IMMUNOL., (1991), vol. 9, pages 457 - 92
    - CAPEL ET AL., IMMUNOMETHODS, (1994), vol. 4, pages 25 - 34
    - DE HAAS ET AL., J. LAB. CLIN. MED., (1995), vol. 126, pages 330 - 41
    - GUYER ET AL., J. IMMUNOL., (1976), vol. 117, page 587
    - KIM ET AL., J. IMMUNOL., (1994), vol. 24, page 249
    - GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, (1996), vol. 202, page 163
    - CLYNES ET AL., PNAS (USA, (1998), vol. 95, pages 652 - 656
    - EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, (1985), vol. 82, page 3688
    - HWANG ET AL., PROC. NATL ACAD. SCI. USA, (1980), vol. 77, page 4030
    - GOADSBY ET AL., N. ENGL. J. MED., (2002), vol. 346, pages 257 - 270
    - TAN ET AL., CLIN. SCI. (LOND)., (1995), vol. 89, pages 565 - 73
    - PLOURDE ET AL., PEPTIDES, (1993), vol. 14, pages 1225 - 1229
    - EUR. J. LMMUNOL., (1999), vol. 29, pages 2613 - 2624
    - KARLSSON, R. ROOS, H. FAGERSTAM, L. PETERSSON, B., METHODS ENZYMOLOGY, (1994), vol. 6, pages 99 - 110
    - KOHLER, B.; MILSTEIN, C., NATURE, (1975), vol. 256, pages 495 - 497
    - BUCK, D. W. ET AL., IN VITRO, (1982), vol. 18, pages 377 - 381
    - WINTER ET AL., NATURE, (1991), vol. 349, pages 293 - 299
    - LOBUGLIO ET AL., PROC. NAT. ACAD. SCI. USA, (1989), vol. 86, pages 4220 - 4224
    - SHAW ET AL., J LMMUNOL., (1987), vol. 138, pages 4534 - 4538
    - BROWN ET AL., CANCER RES., (1987), vol. 47, pages 3577 - 3583
    - RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 327
    - VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536
    - JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525
    - DAUGHERTY ET AL., NUCL. ACIDS RES., (1991), vol. 19, pages 2471 - 2476
    - WINTER ET AL., ANNU. REV. IMMUNOL., (1994), vol. 12, pages 433 - 455
    - MCCAFFERTY ET AL., NATURE, (1990), vol. 348, pages 552 - 553
    - JOHNSON, KEVIN S.; CHISWELL, DAVID J., CURRENT OPINION IN STRUCTURAL BIOLOGY, (1993), vol. 3, pages 564 - 571
    - CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628
    - MARK ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 597
    - GRIFFITH ET AL., EMBO J., (1993), vol. 12, pages 725 - 734
    - MARKS ET AL., BIO/TECHNOL., (1992), vol. 10, pages 779 - 783
    - WATERHOUSE ET AL., NUCL. ACIDS RES., (1993), vol. 21, pages 2265 - 2266
    - PEETERS ET AL., VACCINE, (2001), vol. 19, page 2756
    - LONBERG, N.; D. HUSZAR, LNT.REV.LMMUNOL, (1995), vol. 13, page 65
    - POLLOCK ET AL., J IMMUNOL METHODS, (1999), vol. 231, page 147
    - MORRISON ET AL., PROC. NAT. ACAD. SCI., (1984), vol. 81, page 6851
    - ESCOTT ET AL., BR. J. PHARMACOL., (1993), vol. 110, pages 772 - 776
    - REUTER ET AL., FUNCTIONAL NEUROLOGY, (2000), vol. 15, no. 3
    - FINDEIS ET AL., TRENDS BIOTECHNOL, (1993), vol. 11, page 202
    - WU ET AL., J. BIOL. CHEM., (1988), vol. 263, page 621
    - WU, J. BIOL. CHEM., (1994), vol. 269, page 542
    - ZENKE ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, page 3655
    - WU ET AL., J. BIOL. CHEM., (1991), vol. 266, page 338
    - JOLLY, CANCER GENE THERAPY, (1994), vol. 1, page 51
    - KIMURA, HUMAN GENE THERAPY, (1994), vol. 5, page 845
    - CONNELLY, HUMAN GENE THERAPY, (1995), vol. 1, page 185
    - KAPLITT, NATURE GENETICS, (1994), vol. 6, page 148
    - CURIEL, HUM. GENE THER., (1992), vol. 3, page 147
    - WU, J. BIOL. CHEM., (1989), vol. 264, page 16985
    - PHILIP, MOL. CELL BIOL., (1994), vol. 14, page 2411
    - WOFFENDIN, PROC. NATL. ACAD. SCI., (1994), vol. 91, page 1581
    - BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426
    - HOLLIGER, P. ET AL., PROC. NATL. ACAD SCI. USA, (1993), vol. 90, pages 6444 - 6448
    - POLJAK, R. J. ET AL., STRUCTURE, (1994), vol. 2, pages 1121 - 1123
    - SURESH ET AL., METHODS IN ENZYMOLOGY, (1986), vol. 121, page 210
    - MILLSTEIN; CUELLO, NATURE, (1983), vol. 305, pages 537 - 539
    - JEFFERIS; LUND, CHEM. IMMUNOL., (1997), vol. 65, pages 111 - 128
    - WRIGHT; MORRISON, TIBTECH, (1997), vol. 15, pages 26 - 32
    - BOYD ET AL., MOL. LMMUNOL., (1996), vol. 32, pages 1311 - 1318
    - WITTWE; HOWARD, BIOCHEM., (1990), vol. 29, pages 4175 - 4180
    - WYSS; WAGNER, CURRENT OPIN. BIOTECH., (1996), vol. 7, pages 409 - 416
    - UMANA ET AL., MATURE BIOTECH., (1999), vol. 17, pages 176 - 180
    - HSE ET AL., J. BIOL. CHEM., (1997), vol. 272, pages 9062 - 9070
    - MORGAN ET AL., IMMUNOLOGY, (1995), vol. 86, pages 319 - 324
    - LUND ET AL., J. IMMUNOLOGY, (1996), vol. 157, pages 4963 - 4969
    - LDUSOGIE ET AL., J. IMMUNOLOGY, (2000), vol. 164, pages 4178 - 4184
    - TAO ET AL., J. IMMUNOLOGY, (1989), vol. 143, pages 2595 - 2601
    - JEFFERIS ET AL., IMMUNOLOGICAL REVIEWS, (1998), vol. 163, pages 59 - 76
    - EUR. J. IMMUNOL, (1999), vol. 29, pages 2613 - 2624
    - H. SEE, TAO ET AL., J. IMMUNOLOGY, (1989), vol. 143, pages 2595 - 2601
    - MARKS ET AL., BIO/TECHNOLOGY, (1992), vol. 10, pages 779 - 783
    - BARBAS ET AL., PROC NAT. ACAD. SCI, USA, (1994), vol. 91, pages 3809 - 3813
    - SCHIER ET AL., GENE, (1995), vol. 169, pages 147 - 155
    - YELTON ET AL., J. IMMUNOL., (1995), vol. 155, pages 1994 - 2004
    - JACKSON ET AL., J. IMMUNOL., (1995), vol. 154, no. 7, pages 3310 - 9
    - HAWKINS ET AL., J. MOL. BIOL., (1992), vol. 226, pages 889 - 896
    - BALINT ET AL., GENE, (1993), vol. 137, no. L, pages 109 - 18
    - "A model of evolutionary change in proteins - Matrices for detecting distant relationships", DAYHOFF, M.O., Atlas of Protein Sequence and Structure, NATIONAL BIOMEDICAL RESEARCH FOUNDATION, (1978), vol. 5, pages 345 - 358
    - "Unified Approach to Alignment and Phylogenes", HEIN J., Methods in Enzymology, ACADEMIC PRESS, INC., (1990), vol. 183, pages 626 - 645
    - HIGGINS, D.G.; SHARP, P.M., CABIOS, (1989), vol. 5, pages 151 - 153
    - MYERS, E.W.; MULLER W., CABIOS, (1988), vol. 4, pages 11 - 17
    - ROBINSON, E.D., COMB. THEOR, (1971), vol. 11, page 105
    - SANTOU, N.; NES, M., MOL. BIOL. EVOL., (1987), vol. 4, pages 406 - 425
    - WILBUR, W.J.; LIPMAN, D.J., PROC. NATL. ACAD. SCI. USA, (1983), vol. 80, pages 726 - 730
    - GEERLIGS HJ ET AL., J. IMMUNOL. METHODS, (1989), vol. 124, pages 95 - 102
    - KENNEY JS ET AL., J. IMMUNOL. METHODS, (1989), vol. 121, pages 157 - 166
    - WICHER K ET AL., INT. ARCH. ALLERGY APPL. IMMUNOL., (1989), vol. 89, pages 128 - 135
    - KARLSSON, R. ROOS; H. FAGERSTAM; L. PETERSSON, B, METHODS ENZYMOLOGY, (1994), vol. 6, pages 99 - 110
    - ZIMMERMANN ET AL., PEPTIDES, (1995), vol. 16, pages 421 - 4
    - MALLEE ET AL., J. BIOL. CHEM., (2002), vol. 277, pages 14294 - 8
    - TAN ET AL., CLIN. SCI., (1995), vol. 89, pages 656 - 73
    - WILLIAMSON ET AL., CEPHALALGIA, (1997), vol. 17, no. 4, pages 518 - 24
    - SIPE ET AL., BRAIN RES., (2004), vol. 1028, no. 2, pages 191 - 202
    - MERCHENTHALER ET AL., MATURITAS, (1998), vol. 30, pages 307 - 316
    - KATOVICH ET AL., BRAIN RES., (1989), vol. 494, pages 85 - 94
    - SIMPKINS ET AL., LIFE SCIENCES, (1983), vol. 32, pages 1957 - 1966
 WO2041GB99014
otherUS2002164707
 US2004110170
 WO2007054809
    - Transcript of the Teva Q3 Earning Call, (20171107), URL: https://seekingalpha.com/article/4119613-teva-pharmaceutical-industries-teva-q3-2017-results-earnings-call-transcript?part=single#question-answer-session
    - L. EDVINSSON, "New therapeutic target in primary headaches - blocking the CGRP receptor", Expert Opinion on Therapeutic Targets, (20030000), vol. 7, no. 3, pages 377 - 383
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.